215 related articles for article (PubMed ID: 32159286)
1. Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.
Barbon E; Ayme G; Mohamadi A; Ottavi JF; Kawecki C; Casari C; Verhenne S; Marmier S; van Wittenberghe L; Charles S; Collaud F; Denis CV; Christophe OD; Mingozzi F; Lenting PJ
EMBO Mol Med; 2020 Apr; 12(4):e11298. PubMed ID: 32159286
[TBL] [Abstract][Full Text] [Related]
2. Antithrombin inhibition using nanobodies to correct bleeding in hemophilia.
O'Sullivan JM; O'Donnell JS
EMBO Mol Med; 2020 Apr; 12(4):e12143. PubMed ID: 32212299
[TBL] [Abstract][Full Text] [Related]
3. A single-domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor.
Ferrière S; Kawecki C; Ottavi JF; Denis CV; Kauskot A; Christophe OD; Lenting PJ
J Thromb Haemost; 2019 Dec; 17(12):2035-2046. PubMed ID: 31423724
[TBL] [Abstract][Full Text] [Related]
4. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Girard TJ; Lasky NM; Grunz K; Broze GJ
J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
[TBL] [Abstract][Full Text] [Related]
5. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.
Sehgal A; Barros S; Ivanciu L; Cooley B; Qin J; Racie T; Hettinger J; Carioto M; Jiang Y; Brodsky J; Prabhala H; Zhang X; Attarwala H; Hutabarat R; Foster D; Milstein S; Charisse K; Kuchimanchi S; Maier MA; Nechev L; Kandasamy P; Kel'in AV; Nair JK; Rajeev KG; Manoharan M; Meyers R; Sorensen B; Simon AR; Dargaud Y; Negrier C; Camire RM; Akinc A
Nat Med; 2015 May; 21(5):492-7. PubMed ID: 25849132
[TBL] [Abstract][Full Text] [Related]
6. Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.
Jiang M; Yang F; Jiang Y; Cheng L; Han J; Yi J; Zhang G; Ma Z; Cao L; Zuo B; Zhou L; Huang L; Niu S; Xia Z; Zhou X; Bai X; Esmon NL; Ruan C; Xia L; Han Y; Esmon CT; Wu D; Xu J
Blood Adv; 2022 Jun; 6(11):3304-3314. PubMed ID: 35390147
[TBL] [Abstract][Full Text] [Related]
7. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
[TBL] [Abstract][Full Text] [Related]
8. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
9. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
[TBL] [Abstract][Full Text] [Related]
11. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
[TBL] [Abstract][Full Text] [Related]
12. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
13. Current and emerging biologics for the treatment of hemophilia.
Castaman G; Linari S
Expert Opin Biol Ther; 2019 Aug; 19(8):801-810. PubMed ID: 31039049
[TBL] [Abstract][Full Text] [Related]
14. Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation.
de Laat-Kremers RMW; Ninivaggi M; van Moort I; de Maat M; de Laat B
Sci Rep; 2021 Jul; 11(1):15572. PubMed ID: 34330995
[TBL] [Abstract][Full Text] [Related]
15. Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation.
Nakajima Y; Ogiwara K; Inaba K; Kitazawa T; Nogami K
Thromb Res; 2024 May; 237():14-17. PubMed ID: 38531118
[No Abstract] [Full Text] [Related]
16. Targeting anticoagulant protein S to improve hemostasis in hemophilia.
Prince R; Bologna L; Manetti M; Melchiorre D; Rosa I; Dewarrat N; Suardi S; Amini P; Fernández JA; Burnier L; Quarroz C; Reina Caro MD; Matsumura Y; Kremer Hovinga JA; Griffin JH; Simon HU; Ibba-Manneschi L; Saller F; Calzavarini S; Angelillo-Scherrer A
Blood; 2018 Mar; 131(12):1360-1371. PubMed ID: 29317453
[TBL] [Abstract][Full Text] [Related]
17. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
Liu T; Scallan CD; Broze GJ; Patarroyo-White S; Pierce GF; Johnson KW
Thromb Haemost; 2006 Jan; 95(1):68-76. PubMed ID: 16543964
[TBL] [Abstract][Full Text] [Related]
18. Serpins, New Therapeutic Targets for Hemophilia.
Aymonnier K; Kawecki C; Arocas V; Boulaftali Y; Bouton MC
Thromb Haemost; 2021 Mar; 121(3):261-269. PubMed ID: 32987444
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding.
Hoffman M
Blood Adv; 2021 Sep; 5(18):3736. PubMed ID: 34581771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
